Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status

Published:2020-04-01 Issue:4 Volume:6 Page:542
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kenzik Kelly M.¹²,Bhatia Ravi²,Bhatia Smita¹³

Affiliation:

1. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham

2. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham

3. Division of Pediatric Oncology, University of Alabama at Birmingham, Birmingham

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2759195/jamaoncology_kenzik_2020_br_190013.pdf

Reference15 articles.

1. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.;Sasaki;Lancet Haematol,2015

2. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.;Haque;J Am Pharm Assoc,2017

3. Long-term follow-up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.;Etienne;J Clin Oncol,2017

4. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States.;Padula;J Natl Cancer Inst,2016

5. Generic price competition for specialty drugs: too little, too late?;Cole;Health Aff (Millwood),2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry;Clinical Trials;2023-10-31

2. Management of chronic myeloid leukemia in 2023 – common ground and common sense;Blood Cancer Journal;2023-04-24

3. Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines;Metabolites;2022-12-30

4. Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014–2020;Cancers;2022-03-22

5. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions;Current Hematologic Malignancy Reports;2021-10-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3